BGSI vs COLL

For growth investors, Collegium Pharmaceutical, Inc.

(COLL) is the stronger pick with 23. 6% revenue growth year-over-year, versus 4. 2% for Boyd Group Services Inc. (BGSI). Collegium Pharmaceutical, Inc. (COLL) offers the better valuation at 21. 1x trailing P/E (5. 0x forward), making it the more compelling value choice. Analysts rate Boyd Group Services Inc. (BGSI) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Collegium Pharmaceutical, Inc.

(COLL) is the cheapest at 21. 1x versus Boyd Group Services Inc. at 142. 2x. On forward P/E, Collegium Pharmaceutical, Inc. is actually cheaper at 5. 0x.

Over the past 5 years, Collegium Pharmaceutical, Inc.

(COLL) delivered a total return of +66. 4%, compared to -19. 7% for Boyd Group Services Inc. (BGSI). Over 10 years, the gap is even starker: COLL returned +141. 8% versus BGSI's -19. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Collegium Pharmaceutical, Inc.

(COLL) is the lower-risk stock at 0. 65β versus Boyd Group Services Inc. 's 0. 92β — meaning BGSI is approximately 42% more volatile than COLL relative to the S&P 500. On balance sheet safety, Boyd Group Services Inc. (BGSI) carries a lower debt/equity ratio of 100% versus 3% for Collegium Pharmaceutical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Collegium Pharmaceutical, Inc.

(COLL) is pulling ahead at 23. 6% versus 4. 2% for Boyd Group Services Inc. (BGSI). On earnings-per-share growth, the picture is similar: Collegium Pharmaceutical, Inc. grew EPS -7. 0% year-over-year, compared to -27. 2% for Boyd Group Services Inc.. Over a 3-year CAGR, COLL leads at 18. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Collegium Pharmaceutical, Inc.

(COLL) is the more profitable company, earning 8. 1% net margin versus 0. 6% for Boyd Group Services Inc. — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BGSI leads at 92. 2% versus 24. 0% for COLL. At the gross margin level — before operating expenses — COLL leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Collegium Pharmaceutical, Inc.

(COLL) trades at 5. 0x forward P/E versus 26. 9x for Boyd Group Services Inc. — 21. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COLL: 58. 9% to $58. 00.

In this comparison, BGSI (0.

4% yield) pays a dividend. COLL does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Collegium Pharmaceutical, Inc.

(COLL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65), +141. 8% 10Y return). Both have compounded well over 10 years (COLL: +141. 8%, BGSI: -19. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BGSI (Consumer Cyclical) and COLL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BGSI is a small-cap quality compounder stock; COLL is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.